These results suggest that CD4/CD8 reversal induced by mogamulizumab treatment alone may be insufficient to control ATLL and that the upregulation of Tax‐specific CTLs is essential for long‐term survival, as in the case of ATLL patients with mogamulizumab‐induced skin disorders. The gene discussed is CD4; the disease is skin disorder.